Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

Journal of Hepatology

Volumn 56, Issue 1, 2012, Pages 34-40

  Huang, Chung Feng ^a   Huang, Jee Fu ^a,b,c   Yang, Jeng Fu ^a   Hsieh, Ming Yen ^a   Lin, Zu Yau ^a,b   Chen, Shinn Cherng ^a,b   Wang, Liang Yen ^a,b   Juo, Suh Hang Hank ^a,d   Chen, Ku Chung ^a,d   Chuang, Wan Long ^a,b   Kuo, Hsing Tao ^e,f   Dai, Chia Yen ^a,b   Yu, Ming Lung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

HCV; IL 28B; Tailored regimen; Treatment

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 83555174789     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.03.029     Document Type: Article

References (44)

1. A. Balagopal, D.L. Thomas, and C.L. Thio IL28B and the control of hepatitis C virus infection Gastroenterology 139 2010 1865 1876
2. T. Berg, V. Weich, G. Teuber, H. Klinker, B. Moller, and J. Rasenack Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients Hepatology 50 2009 369 377
3. C.Y. Dai, J.F. Huang, M.Y. Hsieh, N.J. Hou, Z.Y. Lin, and S.C. Chen Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients J Hepatol 50 2009 Apr 712 718
4. P. Ferenci, H. Laferl, T.M. Scherzer, M. Gschwantler, A. Maieron, and H. Brunner Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 2008 451 458
5. T. Fukuhara, A. Taketomi, S. Okano, T. Ikegami, Y. Soejima, and K. Shirabe Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation J Hepatol 52 2010 672 680
6. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
7. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
8. A. Grasso, F. Malfatti, P. De Leo, H. Martines, P. Fabris, and F. Toscanini Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin J Hepatol 51 2009 984 990
9. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
10. C.N. Hayes, M. Kobayashi, N. Akuta, F. Suzuki, H. Kumada, and H. Abe HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy Gut 60 2011 261 267
11. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, and T. Goeser Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
12. C.F. Huang, J.F. Yang, C.Y. Dai, J.F. Huang, N.J. Hou, and M.Y. Hsieh Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C J Infect Dis 201 2010 751 759
13. D.M. Jensen, T.R. Morgan, P. Marcellin, P.J. Pockros, K.R. Reddy, and S.J. Hadziyannis Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kDa)/ribavirin therapy Hepatology 43 2006 954 960 (Pubitemid 43724620)
14. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
15. M. Lagging, R. Wejstal, I. Uhnoo, B. Gerden, B. Fischler, and S. Friman Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations Scand J Infect Dis 41 2009 389 402
16. M. Lindh, M. Lagging, G. Norkrans, and K. Hellstrand A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels Gastroenterology 139 2010 1794 1796
17. C.H. Liu, C.J. Liu, C.L. Lin, C.C. Liang, S.J. Hsu, and S.S. Yang Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial Clin Infect Dis 47 2008 1260 1269
18. A. Mangia, N. Minerva, D. Bacca, R. Cozzolongo, G.L. Ricci, and V. Carretta Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 2008 43 50 (Pubitemid 351171040)
19. A. Mangia, A.J. Thompson, R. Santoro, V. Piazzolla, H.L. Tillmann, and K. Patel An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response Gastroenterology 139 2010 821 827
20. S.M. Martinez, G. Fernandez-Varo, P. Gonzalez, E. Sampson, M. Bruguera, and M. Navasa Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C Aliment Pharmacol Ther 33 2011 138 148
21. J.J. McCarthy, J.H. Li, A. Thompson, S. Suchindran, X.Q. Lao, and K. Patel Replicated association between an interleukin-28B gene variant and a sustained response to pegylated interferon and ribavirin Gastroenterology 138 2010 2307 2314
22. G.W. McCaughan, M. Omata, D. Amarapurkar, S. Bowden, W.C. Chow, and A. Chutaputti Asian Pacific association for the study of the liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection Journal of gastroenterology and hepatology 22 2007 615 633 (Pubitemid 46608388)
23. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
24. S. Nakamoto, T. Kanda, Y. Yonemitsu, M. Arai, K. Fujiwara, and K. Fukai Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction Scand J Gastroenterol 44 2009 872 877
25. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, and T. Mueller Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345
26. M. Rodriguez-Torres, M.S. Sulkowski, R.T. Chung, F.M. Hamzeh, and D.M. Jensen Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population J Viral Hepat 17 2010 139 147
27. C. Sarrazin, S. Susser, A. Doehring, C.M. Lange, T. Muller, and C. Schlecker Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients J Hepatol 54 2011 415 421
28. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
29. H. Shirakawa, A. Matsumoto, S. Joshita, M. Komatsu, N. Tanaka, and T. Umemura Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors Hepatology 48 2008 1753 1760
30. S. Slavenburg, M.H. Lamers, R. Roomer, R.J. de Knegt, M.G. van Oijen, and J.P. Drenth Current clinical care compared with new Dutch guidelines for hepatitis C treatment Neth J Med 67 2009 177 181
31. A.F. Stattermayer, R. Stauber, H. Hofer, K. Rutter, S. Beinhardt, and T.M. Scherzer Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C Clin Gastroenterol Hepatol 9 2011 344 350
32. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171 (Pubitemid 38428955)
33. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, and M.L. Abate IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
34. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, and U. Karey Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
35. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, and N. Sakamoto Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
36. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, and K.V. Shianna Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129
37. C.T. Wai, J.K. Greenson, R.J. Fontana, J.D. Kalbfleisch, J.A. Marrero, and H.S. Conjeevaram A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 2003 518 526 (Pubitemid 36919874)
38. J.F. Yang, C.I. Lin, J.F. Huang, C.Y. Dai, W.Y. Lin, and C.K. Ho Viral hepatitis infections in southern Taiwan: a multicenter community-based study Kaohsiung J Med Sci 26 2010 461 469
39. M.L. Yu, C.F.H.J. Huang, N.C. Chang, J.F. Yang, Z.Y. Lin, and S.C. Chen Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients Hepatology 53 2011 7 13
40. M.L. Yu, and W.L. Chuang Treatment of chronic hepatitis C in Asia: when East meets West J Gastroenterol Hepatol 24 2009 336 345
41. M.L. Yu, W.L. Chuang, C.Y. Dai, L.P. Lee, M.Y. Hsieh, and Z.Y. Lin Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy Transl Res 148 2006 120 127
42. M.L. Yu, C.Y. Dai, J.F. Huang, C.F. Chiu, Y.H. Yang, and N.J. Hou Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial Hepatology 47 2008 1884 1893
43. M.L. Yu, C.Y. Dai, J.F. Huang, N.J. Hou, L.P. Lee, and M.Y. Hsieh A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C Gut 56 2007 553 559
44. S. Zeuzem, M. Buti, P. Ferenci, J. Sperl, Y. Horsmans, and J. Cianciara Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia J Hepatol 44 2006 97 103 (Pubitemid 41772522)